Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 575-577

  Friedman, Joseph H ^a   Shetty, Neetha ^b  

^a BROWN UNIVERSITY   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CYTARABINE; DOXORUBICIN; METOCLOPRAMIDE; PROCHLORPERAZINE; TRIFLUOPERAZINE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CEREBELLAR ATAXIA; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSMETRIA; DYSPHAGIA; FEMALE; GAIT DISORDER; HUMAN; JAW OPENING REFLEX; NYSTAGMUS; PHOTOPHOBIA; PRIORITY JOURNAL; PYRAMIDAL SIGN; SLURRED SPEECH; VISUAL IMPAIRMENT;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ATROPHY; CEREBELLAR ATAXIA; CEREBELLUM; CYTARABINE; FEMALE; HUMANS; INJECTIONS, SPINAL; LEUKEMIA, MYELOCYTIC, ACUTE; MAGNETIC RESONANCE IMAGING; VIDEOTAPE RECORDING;

EID: 0035353754     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1098     Document Type: Article

References (15)

1. Winkelman MD, Hines JD. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983;14:520-527.
2. Herzig RH, Hines JD, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987;5:927-932.
3. Dworkin LA, Goldman RD, Zivin LS, Fuchs PC. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol 1985; 3:613-616.
4. Rudnick SA, Cadman EC, Capizzi RL, et al. High-dose cytosine (HDARAC) in refractory acute leukemia. Cancer 1979;44:1189-1193.
5. Margileth DA, Poplack DG, Pizzopa, et al. Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multi modality therapy. Cancer 1979;39:58-61.
6. Ventura GJ, Keating MJ, Castellanos AM, et al. Reversible bilateral rectus palsy associated with high dose cytosine arabinoside and mitoxantrone therapy. Cancer 1986;58:1633-1635.
7. Malapert D, Degos JD. Painful legs and moving toes. Neuropathy caused by cytarabine. Rev Neurol (Paris). 1989;145:869-871.
8. Luque FA, Selhorst JB, Petruska P. Parkinsonism induced by high dose cytosine arabinoside. Mov Disord 1987;2:219-222.
9. Dunton SF, Nitschke R, Spruce WE, et al. Progressive ascending paralysis following administration of intrathecal and intra venous cytosine arabinoside. Cancer 1986;57:1083-1088.
10. Edan OB, Goldie W, Wood T, et al. Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemias. Cancer 1978;42:53-58.
11. Resar LM, Phillips PC, Kastan MD, et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993;7:117-123.
12. Hasle H. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol 1990;27: 76-78.
13. Vera P, Rohrlich P, Stievenart JL, et al. Contribution of single-photon emission computed tomography in the diagnosis and follow up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia, J Clin Oncol 1999;17:2804-2810.
14. Rubin EH, Andersen JW, Deborah B, et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992;10:948-953.
15. Lazarus HM, Herzig RH, Herzig GP, et al. Central nervous system toxicity of high dose systemic cytosine arabinoside. Cancer 1981; 48:2577-2582.